Onward Med Nv (ONWRF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone to Onward's webcast. Earlier today, we shared our results for the first quarter of 2025 and year-to-date highlights via a press release available on our site. The replay of this webcast will also be made available on our investor relations platform after the session. Before we get started, please take a moment to read this page. Today's presentation includes four looking statements, which should be considered with the appropriate level of caution as outlined in the disclaimer. Today I'm joined by Dave Marver, CEO, and Amaury Fraser, Senior Finance Director. Dave and Amaury will provide an update on our progress before we open for questions. You may submit your questions verbally or via the Q&A module on the platform. With that, I'll hand over to Dave. Thank you. thank you sharon thank you sev thank you to all of you who are joining us today as is our tradition i like to start with a company overview for those of you who are new to the story onward is pioneering therapies to restore movement function and independence in people with spinal cord injury and other movement disabilities we are doing so with three persistent neuromodulation platforms ARC-EX, ARC-IM, and ARC-BCI. ARC-EX delivers ARC therapy externally through the skin. ARC-IM delivers ARC therapy via a fully implanted platform. And ARC-BCI pairs ARC-IM with an implanted brain-computer interface to restore thought-driven movement. We're here because there are 9 million people worldwide living with spinal cord injury. It is a large and expensive unmet need. The TAM is significant at $17 billion, and we're attacking this with innovation. We have 10 FDA breakthrough device designation awards and over 150 issued patents, nearly 300 if you include country validations. In terms of stage, we are now...